119836-12-3

Usage

Uses

Used in Pharmaceutical Research:
4-Chlorophenyl-4-hydroxypiperidine is utilized as a research chemical for studying the effects of serotonin reuptake inhibition on the central nervous system. Its potent action on serotonin pathways makes it a valuable tool in understanding the mechanisms of mood regulation and the development of potential antidepressant medications.
Used in Forensic Toxicology:
In the field of forensic toxicology, 4-CPM is used for the identification and analysis of designer drugs in biological samples. Its detection is crucial for investigating cases of drug abuse, overdose, and related health complications, aiding in the enforcement of drug control regulations.
Used in Drug Policy and Regulation:
4-Chlorophenyl-4-hydroxypiperidine serves as a reference compound in the development and implementation of drug policy and regulation. Its classification as a controlled substance informs legal frameworks and public health strategies aimed at mitigating the risks associated with the use of designer drugs.

Upstream product

• 3592-25-4 1,5-dichloropentan-3-one 
• 142752-12-3 4-(4-hydroxypiperidin-1-yl)aniline 
• 827605-29-8 2-(4-chloro-phenyl)-5,5-dimethyl-[1,3,2]dioxaborinane 
• 1380288-25-4 4-hydroxypiperidin-1-yl benzoate 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 637-87-6 1-Chloro-4-iodobenzene 
• 106-39-8 bromochlorobenzene 
• 72548-31-3 1,5-Dichloropentan-3-ol 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 1054635-91-4 2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]-2-N-phenylacetyl-3',5'-O-(1,1,3,3-tetraisopropyldisiloxyl)guanosine 
• 908140-97-6 N-(9-{(2R,3R,3aR,9aR)-3-[1-(4-Chloro-phenyl)-4-ethoxy-piperidin-4-yloxy]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-9H-purin-6-yl)-2,2-dimethyl-propionamide 
• 908140-96-5 N-(1-{(2R,3R,3aR,9aR)-3-[1-(4-Chloro-phenyl)-4-ethoxy-piperidin-4-yloxy]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-2-oxo-1,2-dihydro-pyrimidin-4-yl)-benzamide 
• 263009-03-6 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-2-N-(phenylacetyl)guanosine 
• 908140-95-4 1-{(2R,3R,3aR,9aR)-3-[1-(4-Chloro-phenyl)-4-ethoxy-piperidin-4-yloxy]-5,5,7,7-tetraisopropyl-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl}-1H-pyrimidine-2,4-dione 
• 263008-98-6 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]-6-N-pivaloyladenosine 
• 263009-01-4 4-N-Benzoyl-2'-O-[1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine 
• 263009-04-7 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]guanosine 
• 263009-02-5 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]cytidine 
• 263008-94-2 2'-O-[1-(4-Chlorophenyl)-4-ethoxypiperidin-4-yl]uridine 
• 263008-84-0 2'-O-[1-(4-Chlorophenyl)-4-methoxypiperidin-4-yl]uridine 
• 263008-89-5 1-(4-Chlorophenyl)-4,4-diethoxypiperidine 
• 263008-90-8 1-(4-Chlorophenyl)-4-ethoxy-1,2,5,6-tetrahydropyridine 
• 115012-53-8 1-(4-Chlorophenyl)-4-methoxy-1,2,5,6-tetrahydropyridine 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE

Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic disorders, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.

Synthesis of hindered anilines: Copper-catalyzed electrophilic amination of aryl boronic esters

No longer a hindrance: Copper-catalyzed electrophilic amination of aryl boronic esters is accomplished under mild reaction conditions using 2.5-5.0 mol % of a catalyst derived from copper tert-butoxide and Xantphos ligand (see scheme). The reaction tolerates a wide range of functional groups and can be used to prepare some of the most hindered anilines made to date. Copyright

NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS

It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -(CR3R4)m-, -CO(CR3R4)n-, -CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

Some observations relating to the use of 1-aryl-4-alkoxypiperidin-4-yl groups for the protection of the 2′-hydroxy functions in the chemical synthesis of oligoribonucleotides

The comparative rates of acid-catalysed removal often 1-aryl-4-methoxypiperidin-4-yl 8 (R = Me) [including the previously reported Ctmp 5 and Fpmp 6] protecting groups for the 2′-hydroxy functions in oligoribonucleotide synthesis are discussed. These studies have led to the development of the 1-(4-chlorophenyl)-4-ethoxypiperidin-4-yl (Cpep) protecting group 8 (R = Et, R1 = R2 = H, R3 = Cl) which is both more stable than the Ctmp and Fpmp groups at pH 0.5 and more labile at pH 3.75. The influence of the ribonucleoside aglycone on the stability of the 2′-O-Fpmp and 2′-O-Ctmp protecting groups both at low and high pH is examined. The Royal Society of Chemistry 2000.

A New Synthesis of 1-Arylpiperidin-4-ols

1,5-Dichloropentan-3-ol (8), which is readily prepared from the corresponding ketone (7), reacts with 2-fluoro-, 4-methyl-, 2-chloro-, 3-chloro-, 4-chloro-, and 3-chloro-4-methyl-anilines in the presence of potassium carbonate and sodium iodide in dimethy